Lindsey Abrahamse
Nurse Practitioner · Mooresville, NCNPI 1821546011
Payments from drug & device makers
Across 137 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$991
- AstraZeneca$511
- Novo Nordisk$226
- AbbVie$164
- Regeneron Healthcare Solutions, Inc.$111
- Boehringer Ingelheim$80
- plus $727 from 24 others
What the payments were for
- Food & beverage$2,811100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 49 | $991 |
| AstraZeneca | 12 | $511 |
| Novo Nordisk | 15 | $226 |
| AbbVie | 9 | $164 |
| Regeneron Healthcare Solutions, Inc. | 4 | $111 |
| Boehringer Ingelheim | 5 | $80 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Lilly USA, LLC | 4 | $58 |
| Bayer | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Baxter Healthcare | 2 | $46 |
| Currax Pharmaceuticals LLC | 3 | $42 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Astellas Pharma US Inc | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Amgen | 2 | $31 |
| IBSA Pharma Inc. | 2 | $29 |
| Pfizer | 2 | $27 |
| Abbott | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| United Therapeutics Corporation | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Phadia US Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Novartis | 1 | $17 |
| Merck | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
| Inogen, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$225
- TRELEGY ELLIPTA$112
How this compares
$2,811 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 813 | $654,896 |
| TezspireTezepelumab-Ekko | 40 | $174,141 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 182 | $138,201 |
| Breo ElliptaFluticasone/Vilanterol | 129 | $58,837 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 69 | $44,770 |
| Spiriva RespimatTiotropium Bromide | 63 | $42,622 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 54 | $28,881 |
| SymbicortBudesonide/Formoterol Fumarate | 53 | $17,107 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 67 | $12,893 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $12,393 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 402 | $12,198 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $9,689 |
| Wixela InhubFluticasone Propion/Salmeterol | 49 | $7,428 |
| Arnuity ElliptaFluticasone Furoate | 26 | $6,855 |
| Ventolin HfaAlbuterol Sulfate | 79 | $5,491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $991 | $775,0481,059 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $511 | $329,449275 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $80 | $71,503117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in Mooresville
- Sandrivette JohnsonRaleigh$573K
- Skyler RogersPinehurst$174K
- Jamie DinerDurham$170K
- Ayeshia WrightMocksville$145K
- Deborah AllenDurham$112K
- Jeanann VawterGastonia$97K
- Terra KampJacksonville$72K
- Mary DilorenzoCharlotte$71K
- Olivia OgburnWinston Salem$70K
- Bridget ArchambaultDurham$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.